Glucagon

The Prime objective of “Glucagon like Peptide 1 (GLP – 1) Agonists Market” report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. Using the industrial figures, the market finds growth figures between the forecast period from 2019 to 2024. In order to present an executive-level model of the market and its future perspectives, the report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Request For Sample Copy of Glucagon like Peptide 1 (GLP – 1) Agonists Market Report @ https://www.industryresearch.co/enquiry/request-sample/13999732

Top Key Players Are:

  • NovoNordisk
  • Sanofi
  • Eli Lilly
  • AstraZeneca

    Glucagon like Peptide 1 (GLP – 1) Agonists Market Report Covers the Top Regions:

    United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, GCC, South Africa, Brazil, Argentina.

    Scope of Glucagon like Peptide 1 (GLP – 1) Agonists Market:

    The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia) and by geography.

    Have Any Query, Ask Our Industry Experts @ https://www.industryresearch.co/enquiry/pre-order-enquiry/13999732

    Key Market Trends: – Constant Trend of High Diabetes Prevalence

    The sales of GLP-1 are directly proportional to the trend of high diabetes prevalence.
    For instance, the percentages of type 2 diabetes in a few significant countries are as follows: China 22.8%, Oman 17.2%, Malaysia 12.9%, and so on.
    It is estimated, worldwide, that approximately USD 8.39 billion is spent on diabetes. The growth in the number of middle-class households, as well as increasing per capita income in these countries, are expected to result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
    Along with this, a few critical factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.

    North America to Dominate the Market in Terms of Revenue

    North America accounts for 77% of the overall GLP-1 market and is expected to witness a growth rate of 6.53%, during the forecast period.
    In the Middle East & Africa, the GLP-1 market is expected to see high growth during the forecast period, with a CAGR of 25.08%.
    In Asia-Pacific, according to the International Diabetes Federation, Japan and Australia have the highest per capita expenditure, of upwards of USD 3,000. However, China and India have the highest diabetes prevalence.

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Purchase Glucagon like Peptide 1 (GLP – 1) Agonists Market Report @ https://www.industryresearch.co/purchase/13999732

    Price of Report: $ 5000 (SUL)

    Detailed TOC of Glucagon like Peptide 1 (GLP – 1) Agonists Market Research Report 2019 – 2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Exenatide
    5.1.1.1 Byetta (Value and Volume 2012-2024)
    5.1.1.2 Bydureon (Value and Volume 2012-2024)
    5.1.2 Liraglutide
    5.1.2.1 Victoza (Value and Volume 2012-2024)
    5.1.3 Lixisenatide
    5.1.3.1 Lyxumia (Value and Volume 2012-2024)
    5.1.4 Dulaglutide
    5.1.4.1 Trulicity (Value and Volume 2012-2024)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 US (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2 Europe
    5.2.2.1 Germany (Value and Volume 2012-2024)
    5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.2 Spain (Value and Volume 2012-2024)
    5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.4 France (Value and Volume 2012-2024)
    5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.5 UK (Value and Volume 2012-2024)
    5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3 Asia-Pacific
    5.2.3.1 Japan (Value and Volume 2012-2024)
    5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.2 China (Value and Volume 2012-2024)
    5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.3 Australia (Value and Volume 2012-2024)
    5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.4 India (Value and Volume 2012-2024)
    5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.5 South Korea (Value and Volume 2012-2024)
    5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.6 Malaysia (Value and Volume 2012-2024)
    5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.7 Indonesia (Value and Volume 2012-2024)
    5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.8 Thailand (Value and Volume 2012-2024)
    5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.9 Philippines (Value and Volume 2012-2024)
    5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4 Latin America
    5.2.4.1 Brazil (Value and Volume 2012-2024)
    5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4.2 Mexico (Value and Volume 2012-2024)
    5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5 Middle East & Africa
    5.2.5.1 South Africa (Value and Volume 2012-2024)
    5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.3 Oman (Value and Volume 2012-2024)
    5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.4 Egypt (Value and Volume 2012-2024)
    5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.5 Iran (Value and Volume 2012-2024)
    5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.1.4 AstraZeneca
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 AstraZeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

    About Industry Research:

    Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

    Contact Us:

    Name: Ajay More

    Organization: Industry Research

    Phone: +44 20 3239 8187 / +14242530807

    Email: [email protected]

    Our latest Report: Global Gaming Desktop Market Offers In-depth Analysis of Types, Applications, and Regional Forecast to 2025

  • Charles Bevers
    News Reporter